Arbutus Biopharma Logo
Arbutus Announces Resignation of Board Member
27 janv. 2023 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Biopharma Logo
Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
05 janv. 2023 07h30 HE | Arbutus Biopharma Corporation
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into...
Arbutus Biopharma Logo
Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection
13 déc. 2022 07h30 HE | Arbutus Biopharma Corporation
Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 2022 (GLOBE...
Arbutus Biopharma Logo
Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update
09 nov. 2022 07h30 HE | Arbutus Biopharma Corporation
Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after...
Arbutus Biopharma Logo
Arbutus to Present at Jefferies London Healthcare Conference
08 nov. 2022 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Biopharma Logo
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
01 nov. 2022 16h01 HE | Arbutus Biopharma Corporation
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in...
Arbutus Biopharma Logo
Arbutus Announces Three Poster Presentations with Clinical Data from AB-729 and Preclinical Data from AB-101 at AASLD - The Liver Meeting® 2022
31 oct. 2022 16h02 HE | Arbutus Biopharma Corporation
Conference Call and Webcast to discuss the new data being presented at AASLD scheduled for 8:45 AM ET, Friday, November 4, 2022 WARMINSTER, Pa., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
Arbutus Biopharma Logo
Arbutus to Report Third Quarter 2022 Financial Results and Provide Corporate Update
26 oct. 2022 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Biopharma Logo
Gaston Picchio, PhD, Chief Development Officer, to Depart Arbutus at Year End
30 sept. 2022 09h00 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...
Arbutus Biopharma Logo
Arbutus to Present at Chardan’s 6th Annual Genetic Medicines Conference
22 sept. 2022 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop...